Graham Capital Management, L.P. Harmony Biosciences Holdings, Inc. Transaction History

Graham Capital Management, L.P.

8 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2024 Aug 14, 2024	SELL	$28.81 - $33.01 $439,093 - $503,105	-15,241 Reduced 59.16%	10,523 $317,000
Q1 2024 May 15, 2024	BUY	$29.93 - $35.06 $771,116 - $903,285	25,764 New	25,764 $865,000
Q2 2023 Aug 14, 2023	SELL	$30.5 - $37.4 $3.16 Million - $3.87 Million	-103,548 Reduced 87.65%	14,585 $513,000
Q1 2023 May 15, 2023	BUY	$30.8 - $53.92 $2.63 Million - $4.61 Million	85,405 Added 260.95%	118,133 $3.86 Million
Q4 2022 Feb 14, 2023	BUY	$45.4 - $60.91 $705,016 - $945,871	15,529 Added 90.29%	32,728 $1.8 Million
Q3 2022 Nov 14, 2022	BUY	$42.06 - $55.45 $723,389 - $953,684	17,199 New	17,199 $761,000
Q2 2022 Aug 15, 2022	SELL	$33.54 - $52.15 $206,807 - $321,556	-6,166 Closed	0 $0
Q1 2022 May 16, 2022	BUY	$33.14 - $51.13 $204,341 - $315,267	6,166 New	6,166 $299,000

243

45.2M

108K

49.2K

Ticker HRMY
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 59,161,400
Market Cap $2.04B
Description
Harmony Biosciences Holdings, Inc., a commercial-stage pharmaceutical company, develops and commercializes therapies for patients with rare neurological disorders in the United States. Its product, WAKIX is a medication for the treatment of excessive daytime sleepiness in adult patients with narcolepsy. The company was formerly known as Harmony ...

Get notified when there are updates to the investment portfolio of Graham Capital Management, L.P., based on Form 13F filings with the SEC.

Stay updated on Graham Capital Management, L.P. with notifications on news.